InFocus is a biotech company utilizing a second-generation, AI-powered discovery engine to identify novel RNA-targeting small molecules. This platform accelerates the process of finding differentiated therapeutic candidates across oncology and neurology indications. The company manages a pipeline progressing from hit identification through in vivo proof-of-concept studies.
Funding
$200K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many disease-causing proteins are considered "undruggable" because they lack traditional binding pockets for small molecule therapeutics, limiting treatment options for diseases like cancer. Existing drug discovery methods struggle to efficiently identify and optimize small molecules that can effectively target RNA.
Solution
InFocus Therapeutics is developing a drug discovery platform that identifies and optimizes small molecule therapeutics that target RNA. The platform integrates experimental technologies with algorithm-driven computational workflows to discover novel, high-potency drug candidates. This approach transforms existing drugs into new molecules with improved properties, addressing the limitations of current drug discovery methods. By targeting RNA, InFocus aims to create new medicines for previously undruggable targets.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for diseases with unmet needs, particularly in oncology.
Features
- Proprietary RNA-targeted drug discovery platform
- Integration of experimental technologies with algorithm-driven computational workflows
- Identification of small molecule therapeutics for undruggable targets
- Transformation of existing drugs into novel, high-potency candidates
- Computational workflow to improve drug properties
- High-throughput screening capabilities